A detailed history of Quest Partners LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 7,014 shares of NTLA stock, worth $138,316. This represents 0.02% of its overall portfolio holdings.

Number of Shares
7,014
Previous 9,807 28.48%
Holding current value
$138,316
Previous $270 Million 41.82%
% of portfolio
0.02%
Previous 0.05%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

SELL
$20.02 - $27.22 $55,915 - $76,025
-2,793 Reduced 28.48%
7,014 $157 Million
Q1 2024

May 09, 2024

SELL
$23.82 - $32.8 $14,506 - $19,975
-609 Reduced 5.85%
9,807 $270 Million
Q4 2023

Feb 09, 2024

BUY
$23.16 - $32.34 $241,234 - $336,853
10,416 New
10,416 $318 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.5B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.